Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Non-randomized Observational (Pharmacoepidemiologic) Cohort Study (Open-label, Multicenter) to Assess the Magnitude of Potential Risk With the Administration of Magnevist® Injection in Patients With Moderate Renal Impairment for the Development of Nephrogenic Systemic Fibrosis (NSF) Based on Diagnostically Specific Clinical and Histopathologic Information.

NCT00744939 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00744939
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00744939 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Non-randomized Observational (Pharmacoepidemiologic) Cohort Study (Open-label, Multicenter) to Assess the Magnitude of Potential Risk With the Administration of Magnevist® Injection in Patients With Moderate Renal Impairment for the Development of Nephrogenic Systemic Fibrosis (NSF) Based on Diagnostically Specific Clinical and Histopathologic Information.
Lead sponsor
Bayer
Phase
Observational
Overall status
Completed
Start date
November 30, 2008
Completion date
November 30, 2013
Enrollment
168 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

fibrosis, kidney failure, renal insufficiency